VIVIO Submits Comments to the FTC on PBM Practices

VIVIO

News Release, 04/25/2022

As a Public Benefit Company with a mission of ensuring that every patient is on an effective therapy at a fair market cost, we believe that regulatory agencies such as the FTC and DOJ have a responsibility to break up the structural monopolies that PBMs, Provider Systems and Health plans have created. These monopolies have resulted in 4% of the world’s population, who are Americans, paying 49% of global healthcare costs. Please click on the link if you would like a copy of VIVIO’s comments to the FTC on PBM Practices and how to regulate them.